In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 201 to 225 of 424

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Lifileucel for previously treated unresectable or metastatic melanoma ID3863	Technology appraisal guidance	TBC
Linzagolix for treating symptoms of endometriosis [ID6357]	Technology appraisal guidance	25 June 2025
Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174]	Technology appraisal guidance	TBC
Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphomas after first-line chemotherapy when a stem cell transplant is suitable [ID3887]	Technology appraisal guidance	11 December 2024
LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]	Technology appraisal guidance	TBC
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (Review of TA909) [ID6434]	Technology appraisal guidance	30 April 2025
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]	Technology appraisal guidance	TBC
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]	Technology appraisal guidance	TBC
Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340	Technology appraisal guidance	TBC
Lurbinectedin for treating advanced small-cell lung cancer on or after platinum-based chemotherapy [ID3872]	Technology appraisal guidance	TBC
Lymphoedema: prevention and management in people with early, locally advanced, and advanced breast cancer (update)	NICE guideline	TBC
Managing common infections - antimicrobial prescribing guidelines	NICE guideline	TBC
Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]	Technology appraisal guidance	TBC
Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]	Technology appraisal guidance	TBC
Maribavir for cytomegalovirus infection after haematopoietic stem cell transplant [ID5075]	Technology appraisal guidance	TBC
Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342]	Technology appraisal guidance	26 February 2025
Masitinib with riluzole for treating amyotrophic lateral sclerosis ID6257	Technology appraisal guidance	TBC
Maternal and child nutrition	NICE guideline	15 January 2025
Melanoma (metastatic) - talimogene laherparepvec [ID508]	Technology appraisal guidance	28 September 2016
Meningitis (bacterial) and meningococcal disease update	Quality standard	4 December 2024
Menopause: diagnosis and management	NICE guideline	7 November 2024
Mental health guidelines	NICE guideline	TBC
Mirikizumab for treating moderately to severely active Crohn's disease [ID6244]	Technology appraisal guidance	TBC
Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]	Technology appraisal guidance	TBC
Molnupiravir for treating COVID 19 [ID6340]	Technology appraisal guidance	29 January 2025

Results per page

10
25
50
All